Neurotensin polyplex as an efficient carrier for delivering the human GDNF gene into nigral dopamine neurons of hemiparkinsonian rats

NT-polyplex: a new tool for therapeutic gene delivery to neuroblastoma tumors

Neurotensin (NT)-polyplex is a nonviral system for the targeted gene delivery to cells that express and internalize the high-affinity NT receptor (NTSR1). In hemiparkinsonian rats, we previously demonstrated the morphological and functional recovery from dopaminergic neurodegeneration using the NT-polyplex as a vehicle to transfect a neurotrophic gene. The main objective of this work was to demonstrate the feasibility of NT-polyplex to transfect reporter or therapeutic genes into neuroblastoma tumors through the blood stream or by intratumoral injection. N1E-115 cells known to express NTSR1 were allografted into athymic mice to generate the neuroblastoma tumor model. Both routes of administration allowed the NT-polyplex to reach and transfect tumoral cells. A low transgene expression was also detected in intestinal tract cells only after the injection into the blood stream. The transfection of the thymidine kinase (HSVTK) suicide gene followed by ganciclovir (GCV) treatment decreased the size and weight of neuroblastoma tumors by 30-50% and increased apoptosis compared to controls. This study shows the potential of the NT-polyplex as specific gene-transfer system for NTSR1 cancer cells.

GDNF isoform affects intracellular trafficking and secretion of GDNF in neuronal cells

Glial cell line derived neurotrophic factor (GDNF) plays a critical role in central and peripheral neuron survival and function. In human and rodents, GDNF exists in an alternative spliced isoform (GDNF Delta 78), which has a 78 bp deletion in the pro-region of the GDNF encoding sequence. Whether the GDNF isoform affects GDNF function is unknown. Here, we investigated the secretion and intracellular localization of the GDNF Delta 78 isoform in neuronal cell populations. Our data indicate that a decreased secretion and an abnormal intracellular distribution of GDNF Delta 78 occurred in neuronal cells. The colocalization studies revealed much more localization of GDNF Delta 78 with Golgi marker-TGN38, which indicates that the accumulation of GDNF Delta 78 in the Golgi apparatus might in part account for its intracellular trafficking and secretion deficit. To our knowledge, it is reported for the first time that the GDNF Delta 78 isoform has a deficit in GDNF intracellular trafficking and secretion.

Pitx3 promoter directs Cre-recombinase specifically in a human neuroblastoma cell line

The Pitx3 gene is a homeobox transcription factor. This gene is expressed only in midbrain dopaminergic-neurons in the central nervous system, where its expression is important for development and survival of mesencephalic-dopaminergic neurons. The promoter region of the Pitx3 gene is not yet completely delimited. We used the Cre-loxP system to demonstrate the efficiency and specificity of a 4.2-kbp sequence in the 5'-flanking region of the Pitx3-gene promoter inserted in the 5'-terminus of the Cre-recombinase gene. A Cre-recombinase-reporter assay indicated that this 5'-flanking region possesses promoter activity. The cell-specific gene regulation of the Pitx3 promoter in neurons was demonstrated by a reverse-transcription polymerase chain reaction (RT-PCR) and Western blot detection of Cre-recombinase in SH-SY5Y cells but not in MCF7 cells. Functionality of the Cre-recombinase was confirmed in vitro. The Pitx3-promoter-Cre cassette here described can be used to develop transgenic mice with the specific expression of Cre-recombinase in midbrain-dopaminergic neurons to elucidate the gene function in which the conventional knockout leads to an early lethal phenotype. Such specific expression of the Pitx3 promoter may be used for gene therapy studies of Parkinson's disease.

Nonviral approaches for neuronal delivery of nucleic acids

The delivery of therapeutic nucleic acids to neurons has the potential to treat neurological disease and spinal cord injury. While select viral vectors have shown promise as gene carriers to neurons, their potential as therapeutic agents is limited by their toxicity and immunogenicity, their broad tropism, and the cost of large-scale formulation. Nonviral vectors are an attractive alternative in that they offer improved safety profiles compared to viruses, are less expensive to produce, and can be targeted to specific neuronal subpopulations. However, most nonviral vectors suffer from significantly lower transfection efficiencies than neurotropic viruses, severely limiting their utility in neuron-targeted delivery applications. To realize the potential of nonviral delivery technology in neurons, vectors must be designed to overcome a series of extra- and intracellular barriers. In this article, we describe the challenges preventing successful nonviral delivery of nucleic acids to neurons and review strategies aimed at overcoming these challenges.